Israel Tojal Da Silva

Israel Tojal Da Silva

Auto-generated profile, based on publicly available information

Israel Tojal Da Silva

Camargo Cancer Center, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
EBEmilie Battivelli
Emilie Battivelli
MDMatthew S. Dahabieh
Matthew S. Dahabieh
MAMohamed Abdel-Mohsen
Mohamed Abdel-Mohsen
JSJ. Peter Svensson
J. Peter Svensson
ISIsrael Tojal Da Silva
Israel Tojal Da Silva
EVEric Verdin
Eric Verdin
Human immunodeficiency virus (HIV) infection cannot be cured due to a small reservoir of latently infected CD4 + T cells in treated patients. The “shock and kill” approach proposes to eliminate the reservoir by inducing its activation and the direct or indirect killing of infected cells. Current latency reversing agents (LRAs) do not reduce the viral reservoir in treated patients. We use a novel dual-fluorescent HIV reporter to identify and purify latent cells, and to determine the fraction of latent cells that undergo viral reactivation after infection of primary CD4 + T cells. Unexpectedly, LRAs reactivate less than 5% of latent proviruses. Analysis of HIV integration sites from induced and non-induced latent populations reveals distinct provirus integration sites between these two populations in terms of chromatin functional states. These findings challenge “shock and kill”, and suggest the need of more potent LRAs in combination with immunomodulatory approaches to eradicate HIV reservoir.